Evidence map›Paper›PMID 29427624›Full record

ReviewBiochemical pharmacology2018

Adenosine metabolism, immunity and joint health.

György Haskó, Luca Antonioli, Bruce N Cronstein

Abstract readReview
In one paragraph

Review in Biochemical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 64 citations in OpenAlex.

  1. 4'-Thionucleosides as adenosine AMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Roles of metabolic dysregulation in osteoarthritis.Frontiers in cell and developmental biology · 2026
    Review
  3. Review
  4. The Role of Adenosine in Overcoming Resistance in Sarcomas.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. AInternational review of neurobiology · 2023
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Plasma Metabolomic Profiling of Patients Recovered From Coronavirus Disease 2019 (COVID-19) With Pulmonary Sequelae 3 Months After Discharge.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

György HaskóDepartment of Anesthesiology, Columbia University, New York, NY 10032, USA.
Luca AntonioliDepartment of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Bruce N CronsteinDepartment of Medicine, New York University, NY 10016, USA. Electronic address: bruce.cronstein@nyumc.org.
Columbia University · USNew York University · USUniversity of Pisa · IT

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
Institutional Clinical and Translational Science AwardUL1TR000038 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL, HOCHMAN, JUDITH S · 2012 to 2014
$16.8M
Purinergic signaling in trauma and sepsisR01GM066189 · NIGMS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI HASKO, GEORGE · 2002 to 2020
$4.7M
The Pharmacology of Dermal Fibrosis R01AR056672 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2009 to 2018
$4.6M
Purinergic Stimulation of Bone RegenerationR01AR068593 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI COELHO, PAULO G, CRONSTEIN, BRUCE NEIL · 2015 to 2019
$2.8M
Purinergic signaling in granuloma-forming Th2 immunityR01DK113790 · NIDDK · RBHS-NEW JERSEY MEDICAL SCHOOL · PI GAUSE, WILLIAM CLARK, HASKO, GEORGE · 2017 to 2020
$1.9M
Soluble E-NTPDase for sepsisR41GM120838 · NIGMS · PURINE PHARMACEUTICALS, INC. · PI HASKO, GEORGE · 2017 to 2017
$225k
NCATS NIH HHS UL1 TR000038NCATS NIH HHS UL1 TR001445NIAMS NIH HHS R01 AR056672NIAMS NIH HHS R01 AR068593NIDDK NIH HHS R01 DK113790NIGMS NIH HHS R01 GM066189NIGMS NIH HHS R41 GM120838
6 · The paper itself

Abstract

The purine nucleoside adenosine is a present in most body fluids where it regulates a wide variety of physiologic and pharmacologic processes. Adenosine mediates its effects through activating 4 G protein-coupled receptors expressed on the cell membrane: A1, A2A, A2B, and A3. The adenosine receptors are widely distributed in the body, and tissues with high expression include immune tissues, cartilage, bone, heart, and brain. Here we review the source and metabolism of adenosine and the role of adenosine in regulating immunity and cartilage biology.

Indexed as

Adaptive ImmunityHomeostasisImmunity, InnateAdenosineAnimalsCartilageHumansJointsReceptors, Purinergic P1Th1 CellsTh2 CellsAdenosineReceptors, Purinergic P1AdenosineAdenosine metabolismAdenosine receptorFibrosisOsteoarthritisType 2 immunity

Identifiers

PMID29427624
PMCPMC5899962
OpenAlexW2790041631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.